ArticleJournal of movement disorders2026
Association Between Statin Use and Mortality in Adults With Parkinson's Disease: A Nationwide Cohort Study.
Article in Journal of movement disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lovastatin Potentiates the Function of α7-Nicotinic Acetylcholine Receptors.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The influence of cholesterol on the 5-year all-cause mortality of Parkinson patients with or without deep brain stimulation.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThe impact of statin use on the progression and survival of patients with Parkinson's disease (PD) remains unclear. Moreover, evidence in Asian populations is limited. This study aimed to assess the associations between statin prescription, cumulative dosage, and all-cause mortality in PD patients.
methodsThis retrospective cohort study was conducted using sample data obtained from the Korean National Health Insurance Service (KNHIS) claims database. The study included 3,152 adults who were diagnosed with PD and whose history of statin use and cumulative dose information were obtained from claims records. Data were collected from the KNHIS database, and all eligible participants were followed longitudinally to determine all-cause mortality. The primary outcome was all-cause mortality, and the exposures were statin use (yes or no) and cumulative dose. The analysis was conducted using Cox proportional hazards regression adjusted for relevant covariates.
resultsStatin use was associated with a lower risk of all-cause mortality (hazard ratio [HR], 0.600; 95% confidence interval [CI], 0.521-0.691). Among statin users, a higher cumulative statin dose was linked to a further reduction in mortality (HR, 0.800; 95% CI, 0.761-0.842).
conclusionStatin use and increased cumulative exposure were associated with reduced all-cause mortality in patients with PD, and these findings suggest a potential survival benefit and warrant further investigation in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.